These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 18495268
1. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach. Giamouzis G, Giannakoulas G, Tsarpalis K, Agha SA, Georgiopoulou V, Kalogeropoulos A, Karvounis H, Butler J. Int J Cardiol; 2008 Aug 01; 128(1):91-3; author reply 94-6. PubMed ID: 18495268 [No Abstract] [Full Text] [Related]
3. A struggle to SURVIVE: to abandon or not to abandon levosimendan? Butler J, Giamouzis G, Giannakoulas G. Cardiovasc Drugs Ther; 2007 Oct 01; 21(5):401-2. PubMed ID: 17701453 [No Abstract] [Full Text] [Related]
4. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure. Oner E, Erturk M, Birant A, Kurtar Mansıroglu A, Akturk IF, Karakurt H, Yalcin AA, Uzun F, Somuncu MU, Yildirim A. Cardiol J; 2015 Oct 01; 22(1):87-93. PubMed ID: 24846511 [Abstract] [Full Text] [Related]
5. How to treat acute decompensated heart failure in the 'beta-blocker era'? Marcondes-Braga FG, Mangini S, Ayub-Ferreira SM, Bocchi EA, Bacal F. Eur J Heart Fail; 2010 Aug 01; 12(8):893-4. PubMed ID: 20675672 [No Abstract] [Full Text] [Related]
9. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study. Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Põder P, Sarapohja T. Eur J Heart Fail; 2008 Dec 01; 10(12):1246-54. PubMed ID: 18945637 [Abstract] [Full Text] [Related]
10. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Eur J Heart Fail; 2007 Jan 01; 9(1):75-82. PubMed ID: 16829185 [Abstract] [Full Text] [Related]
17. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. Branzi G, Malfatto G, Villani A, Ciambellotti F, Revera M, Giglio A, Rosa FD, Facchini M, Parati G. J Cardiovasc Med (Hagerstown); 2010 Sep 02; 11(9):662-8. PubMed ID: 20613551 [Abstract] [Full Text] [Related]
19. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I. Eur J Heart Fail; 2005 Aug 02; 7(5):882-7. PubMed ID: 15921958 [Abstract] [Full Text] [Related]
20. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure. Cetin M, Uçar O, Cicekçioğlu H, Güven Cetin Z, Sahin M, Vasfi Ulusoy F, Aydoğdu S. Acta Cardiol; 2012 Jun 02; 67(3):317-23. PubMed ID: 22870740 [Abstract] [Full Text] [Related] Page: [Next] [New Search]